These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37467877)

  • 1. Regulatory benefit-risk assessment of oncology drugs: A systematic review of FDA and EMA approvals.
    Pinto CA; Balantac Z; Mt-Isa S; Liu X; Bracco OL; Clarke H; Tervonen T
    Drug Discov Today; 2023 Oct; 28(10):103719. PubMed ID: 37467877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
    Kühler TC; Bujar M; McAuslane N; Liberti L
    BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
    Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
    BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information.
    Lau C; Jamali F; Loebenberg R
    J Pharm Pharm Sci; 2022; 25():227-236. PubMed ID: 35760071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.
    Jenei K; Gentilini A; Haslam A; Prasad V
    Lancet Oncol; 2024 Aug; 25(8):979-988. PubMed ID: 39004098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
    Goring S; Taylor A; Müller K; Li TJJ; Korol EE; Levy AR; Freemantle N
    BMJ Open; 2019 Feb; 9(2):e024895. PubMed ID: 30819708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
    Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
    JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded Access as a source of real-world data: An overview of FDA and EMA approvals.
    Polak TB; van Rosmalen J; Uyl-de Groot CA
    Br J Clin Pharmacol; 2020 Sep; 86(9):1819-1826. PubMed ID: 32200551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
    Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
    JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021).
    Gnanasakthy A; Levy C; Norcross L; Doward L; Winnette R
    Value Health; 2023 Jun; 26(6):893-901. PubMed ID: 36746305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis.
    Leo CP; Hentschel B; Szucs TD; Leo C
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32069837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States.
    Zaim R; Redekop K; Uyl-de Groot CA
    J Cancer Policy; 2022 Sep; 33():100346. PubMed ID: 35779788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
    Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
    Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.
    Arondekar B; Duh MS; Bhak RH; DerSarkissian M; Huynh L; Wang K; Wojciehowski J; Wu M; Wornson B; Niyazov A; Demetri GD
    Clin Cancer Res; 2022 Jan; 28(1):27-35. PubMed ID: 34667027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
    Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
    BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
    Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
    Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.